Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Moleculin Biotech ( (MBRX) ).
On July 30, 2025, Moleculin Biotech announced it received a Notice of Intent to Grant for a European patent application related to its drug candidate Annamycin. This patent is expected to solidify the company’s exclusivity in the European Union for Annamycin, which is being developed as a non-cardiotoxic anthracycline for treating AML and soft tissue sarcoma lung metastases. The patent, once granted, will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, potentially extending until 2040. This development enhances Moleculin’s market position in Europe and validates Annamycin’s potential as a transformative therapeutic candidate.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. The company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
Average Trading Volume: 5,244,330
Technical Sentiment Signal: Sell
Current Market Cap: $16.62M
For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.